Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant price inflation of its shares during a specific period [6]. Group 1: Allegations - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders and affiliates allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that inflated the stock price [6]. Group 2: Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [6]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [6]. Group 3: Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [6]. Group 4: Legal Process - Investors who purchased Charming shares between October 10, 2025, and November 12, 2025, have until February 17, 2026, to apply to be appointed as lead plaintiff in the lawsuit [6].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Ltd. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2025, to November 12, 2026 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Charming securities during the specified Class Period [2]. - Allegations include failure to disclose a fraudulent stock promotion scheme, insider trading activities, and misleading public statements regarding the company's business and operations [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by February 17, 2026, although participation in any recovery does not require this role [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only collect fees if the lawsuit is successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Ltd. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations that Charming and certain officers and/or directors engaged in securities fraud [2]. - Investors have until February 17, 2026, to request to be appointed as Lead Plaintiff if they purchased Charming securities during the Class Period [2]. Group 2: Stock Performance and SEC Action - On November 11, 2025, Charming's stock closed at $29.36, with an intraday high of $31.70, and had approximately 17.18 million shares outstanding, resulting in a market capitalization of around $504 million [4]. - Following this, the SEC halted trading of Charming securities from November 12 through 25, 2025, due to allegations of price manipulation through social media, which was part of a "pump-and-dump" scheme [4].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the period from October 10, 2025, to November 12, 2025 [6]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [6]. Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [6]. - The stock was subject to an illicit promotion scheme that created a buying frenzy among retail investors through sensational claims made by impersonators in online forums and social media [6]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the necessary information to lift the suspension [6]. Legal Options for Investors - Investors who purchased Charming shares and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. for legal options, with a deadline of February 17, 2026, to apply as lead plaintiff in the lawsuit [4][6].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Charming Medical Limited regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Investigation and Legal Actions - The U.S. Securities and Exchange Commission (SEC) issued an order to halt trading of Charming Medical securities due to potential manipulation through social media recommendations aimed at artificially inflating the price and trading volume of the company's securities [3]. - Trading in Charming Medical's securities was suspended starting on November 12, 2025, following the SEC's order [3]. Group 2: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for the rights of victims of securities fraud and corporate misconduct [4]. - The firm has successfully recovered numerous multimillion-dollar damages awards on behalf of class members [4].

Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for allegedly engaging in a fraudulent stock promotion scheme that misled investors and artificially inflated its stock price [1][2]. Allegations - The complaint alleges that Charming Medical failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that were driving the stock price [2]. Stock Price Surge - In the weeks leading up to November 12, 2025, Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite a lack of fundamental news justifying such a rise [3]. - Investigations revealed that the stock was subject to an illicit social-media-based promotion scheme that created a buying frenzy among retail investors through sensational but baseless claims [3]. - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended due to the company's failure to provide required information to regulators [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit papers to the court by February 17, 2026, but participation is not required to be eligible for recovery [4]. - Individuals can choose to remain absent class members if they do not wish to take action [4]. Legal Representation - All representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [5].

Core Viewpoint - Charming Medical Limited is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Group 1 - The lawsuit has been initiated by the DJS Law Group, indicating potential legal challenges for Charming Medical Limited [1] - The allegations pertain to securities law violations, which could lead to significant financial repercussions for the company [1]

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited for alleged violations of securities laws, specifically related to misleading statements made by the company during a specified class period [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from October 21, 2025, to November 12, 2025 [2]. - The lawsuit claims that Charming Medical made false and misleading statements that led to the suspension of trading of its shares by the SEC due to an investigation into a scheme to artificially inflate the company's share price [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although being appointed as lead plaintiff is not necessary to participate in any recovery [2]. - The deadline for participation in the lawsuit is set for February 17, 2026 [2]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, indicating a strong reputation in the field [4].

Core Viewpoint - MCTA investors have the opportunity to lead a securities fraud lawsuit against Charming Medical Limited with the Schall Law Firm [1] Group 1 - The lawsuit is focused on allegations of securities fraud involving Charming Medical Limited [1] - The Schall Law Firm is representing MCTA investors in this legal action [1] - This case presents a potential opportunity for investors to seek redress for alleged financial misconduct [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Charming Medical Limited on behalf of investors who acquired its securities during the specified class period [1] Group 1 - The lawsuit pertains to investors who purchased or acquired Charming Medical Limited securities between October 10, 2025, and November 12, 2025 [1] - Investors have until February 17, 2026, to file a lead plaintiff motion [1]